1628-79-1

Basic information

• Product Name: 1-(3,7-dinitro-10H-phenothiazin-10-yl)ethanone
• CAS NO: 1628-79-1
• Molecular Formula: C₁₄H₉N₃O₅S
• Molecular Weight: 331.3034
• Mol File: 1628-79-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 648.2°C at 760 mmHg
• Flash Point: 345.8°C
• Density: 1.566g/cm³
• Vapor Pressure: 1.09E-16mmHg at 25°C
• Refractive Index: 1.716
• CAS DataBase Reference: 1-(3,7-dinitro-10H-phenothiazin-10-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,7-dinitro-10H-phenothiazin-10-yl)ethanone(1628-79-1)
• EPA Substance Registry System: 1-(3,7-dinitro-10H-phenothiazin-10-yl)ethanone(1628-79-1)

Safety Data

• Hazardous Substances Data: 1628-79-1(Hazardous Substances Data)

Usage

General Description

1-(3,7-dinitro-10H-phenothiazin-10-yl)ethanone is a chemical compound with the molecular formula C15H9N3O6S. It is a derivative of phenothiazine and contains a dinitrophenyl group and an ethanone group. 1-(3,7-dinitro-10H-phenothiazin-10-yl)ethanone is a solid at room temperature and is yellow in color. It is used in research and chemical synthesis, and its properties and potential uses are still being explored. It is important to handle this compound with caution and follow proper safety protocols due to its potential reactivity and toxicity.

Upstream product

• 1628-77-9 3-nitro-10H-phenothiazine 
• 92-84-2 10H-phenothiazine 
• 1747-90-6 3,11-dinitro-10H-phenothiazine 
• 108-24-7 acetic anhydride 

Downstream Products

• 59436-29-2 10-acetyl-N,N'-bis-(2-hydroxy-benzylidene)-10H-phenothiazine-3,7-diamine 
• 59436-28-1 10-acetyl-N,N'-dibenzylidene-10H-phenothiazine-3,7-diamine 
• 7506-02-7 10-acetyl-3,7-dinitro-10H-phenothiazine 5-oxide 

Relevant articles and documents

Therapeutic use of diaminophenothiazines

The present invention relates generally to methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.

METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS

This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesis and/or purification of certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as "diaminophenothiazinium compounds") including Methylthioninium Chloride (MTC) (also known as Methylene Blue). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis, etc., for example, a tauopathy; a disease of tau protein aggregation; Alzheimer's disease (AD); Pick's disease; Progressive Supranuclear Palsy (PSP); fronto temporal dementia (FTD); parkinsonism linked to chromosome 17 (FTDP-17); disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC); pallido-ponto-nigral degeneration (PPND); Guam-ALS syndrome; pallido-nigro-luysian degeneration (PNLD); cortico-basal degeneration (CBD); mild cognitive impairment (MCI); skin cancer; melanoma; methemoglobinemia; a viral infection; a bacterial infection; a protozoal infection; a parasitic infection; malaria; visceral leishmaniasis; African sleeping sickness; toxoplasmosis; giardiasis; Chagas' disease; Hepatitis C virus (HCV) infection; human immunodeficiency virus (HIV) infection; West Nile virus (WNV) infection; a synucleinopathy; Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); drug-induced parkinsonism; and pure autonomic failure (PAF).